NasdaqCM - Nasdaq Real Time Price USD

Silexion Therapeutics Corp (SLXNW)

Compare

0.0900

+0.0020

+(2.27%)

As of 10:40:09 AM EST. Market Open.

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary s

GlobeNewswire yesterday

SLXN
+2.44%
SLXNW
+2.27%
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions.

Business Wire 2 days ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastasesCayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new pre

GlobeNewswire 3 days ago

SLXN
+2.44%
SLXNW
+2.27%
PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

NEW YORK, January 16, 2025--PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new preclinical data for SIL-204, its next-generation siRNA candidate. These findings reaffirm the company’s innovative approach to addressing some of the most challenging cancers, including pancreatic cancer, which is marked by KRAS mutations in over 90% of cases.

Business Wire 14 days ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equiv

GlobeNewswire 15 days ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Significant new preclinical results demonstrate synergistic activity of SIL-204 with 5-fluorouracil and irinotecan as well as gemcitabine, reinforcing its potential to improve outcomes in KRAS-mutated pancreatic cancer and other cancers treated with similar therapies.Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclini

GlobeNewswire 15 days ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancersCayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, Californ

GlobeNewswire 18 days ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics, Evonik collaborate on siRNA formulation development

Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy. Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying vari

TipRanks last month

SLXN
+2.44%
SLXNW
+2.27%
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

LONDON, December 17, 2024--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically "undruggable" oncogenic drivers. Silexion

Business Wire last month

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Silexion is collaborating with Evonik on the development of a long-acting siRNA PLGA microparticle formulation, which has demonstrated high efficacy in preclinical models for KRAS-mutated cancersCayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today revealed its ongoing collaboration with Evonik, a global leader in specialty chemicals, for th

GlobeNewswire last month

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutationsCayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon P

GlobeNewswire last month

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiativesGRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of i

GlobeNewswire 2 months ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida. Ilan Hadar, Chief Executive Officer will deliver a company presentation titled “Transformi

GlobeNewswire 2 months ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications. GRAND CAYMAN, CAYMAN ISLANDS / ACCESSWIRE / November 14, 2024 / Silexion Therapeutics ...

ACCESS Newswire 2 months ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

GRAND CAYMAN, CAYMAN ISLANDS / ACCESSWIRE / October 9, 2024 / Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its ...

ACCESS Newswire 3 months ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

GRAND CAYMAN, Cayman Island, October 01, 2024--Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation. These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis

Business Wire 3 months ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

GRAND CAYMAN, Cayman Island, September 24, 2024--Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new findings from its Phase 2 trial of LODER™ in patients with non-resectable locally advanced pancreatic cancer (LAPC) which bear the KRAS G12D or G12V mutation (approximately 70% of pancreatic cancer patients). Overall the updated analysis reveals a 56

Business Wire 4 months ago

SLXN
+2.44%
SLXNW
+2.27%
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

LONDON, September 09, 2024--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion presents an interesting opportunity in the rapidly growing field of targeted cancer treatments, particularly in addressing the challenges of pancrea

Business Wire 4 months ago

SLXN
+2.44%
SLXNW
+2.27%
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. A company presentation will be available on demand here as of Monday, September 9 at 7:00 AM ET. Si

GlobeNewswire 4 months ago

SLXN
+2.44%
SLXNW
+2.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Silexion Therapeutics Corp (SLXNW)

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion Therapeutics, Evonik collaborate on siRNA formulation development

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference